Table 1

Specificity spectrum of coumestrol
Protein kinase Kinase activity %
CK2 0
CK1 119
DYRK1a 64
HER2 98
MAP2K 139
MET 101
VEGFR 41
AKT2 164
GSK3b 60
SRC 166
PAK1 129
mTOR 110
JAK2 53

Remaining kinase activity was determined in the presence of 10 μM coumestrol and 10 μM ATP and expressed as a percentage of the control without inhibitor. CK2, Casein kinase 2; CK1, Casein kinase 1; DYRK, Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase; HER2, Human epidermal growth factor receptor 2; MAP2K, Mitogen-activated protein kinase kinase; c-Met, c-Met receptor tyrosine kinase; VEGFR3, Vascular endothelial growth factor receptor 3; AKT, also known as protein kinase B (PKB); GSK, Glycogen synthase kinase; SRC, src Gene encoded non-receptor tyrosine kinase; PAK1, p21 Protein (Cdc42/Rac)-activated kinase 1; mTOR, Mammalian target of rapamycin; JAK, Janus kinase.

Liu et al.

Liu et al. BMC Pharmacology and Toxicology 2013 14:36   doi:10.1186/2050-6511-14-36

Open Data